PURPLE BIOTECH Business Summary

Purple Biotech Ltd. (PPBT) is a clinical-stage biopharmaceutical company that operates on a research and development-driven business model, currently generating no revenue from product sales. The company’s financial strategy relies on securing capital through public offerings and strategic partnerships to fund the clinical advancement of its oncology pipeline. Its primary business segments are centered on three first-in-class therapeutic candidates: CM24, a monoclonal antibody targeting CEACAM1 to overcome immune evasion; NT219, a small molecule dual inhibitor of IRS1/2 and STAT3 designed to bypass drug resistance; and the CAPTN-3 tri-specific antibody platform, which includes the preclinical candidate IM1240. Within the competitive landscape, Purple Biotech operates as a small-cap innovator alongside peers such as Briacell Therapeutics, BioLine RX, and Compugen. It distinguishes itself by specifically targeting the tumor microenvironment (TME) and utilizing biomarker-driven patient selection to improve clinical outcomes in hard-to-treat cancers like pancreatic ductal adenocarcinoma. The leadership team is headed by Chief Executive Officer Gil Efron, who has spearheaded the company’s strategic pivot toward its current oncology focus since 2022. The executive suite includes Chief Financial Officer Shai Lankry, appointed in May 2025, and Dr. Hadas Reuveni, who serves as the Vice President of Research & Development and was the founder of TyrNovo (acquired by the company). Clinical operations are managed by Dr. Michael Schickler, Head of Clinical & Regulatory Affairs. The Board of Directors is chaired by Dr. Eric Rowinsky, a renowned oncologist and former CMO of Stemline Therapeutics, with long-standing director and former CEO Isaac Israel providing institutional continuity. Notable institutional backing includes Armistice Capital LLC, which remains a significant shareholder as the company advances its lead assets through Phase 2 clinical milestones.